Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma

Trial Profile

Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs GPX 150 (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors Gem Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2017 Results published in the Monopar Therapeutics Media Release.
    • 22 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top